-
Mercados
-
Acções
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
índices
A milestone in a decade of transformationEuronext joins the CAC 40®Read moreAs of 22 September 2025, Euronext has officially joined the CAC 40®, France’s flagship blue-chip index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fundos
-
Obrigações
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Warrants & Certificados
-
Derivados
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Matérias-Primas
- Vista global
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Entrega e liquidação
- Especificações e disposições
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Recursos
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
CARMAT
Identification
Listing sponsor / Agent
Dexia Securities France
ISIN code
FR0010907956
Exchange / Market
Euronext Growth
Trading location
Paris
ICB
Medical Equipment
Activity description
Créée le 30 juin 2008, CARMAT SAS est une Jeune Entreprise Biomédicale Innovante financée par TRUFFLE CAPITAL, EADS et le Professeur Carpentier avec le soutien d’OSEO.
L’objectif de Carmat est de proposer un cœur artificiel totalement implantable, incluant les ventricules droit et gauche et dont la conception vise à se rapprocher au maximum du cœur humain. Comptant près de 15 années de développement, ce projet est issu de la collaboration du chirurgien cardio-vasculaire Alain Carpentier et de EADS, dans la mise en œuvre de biomatériaux et de technologies de pointe appliquées au domaine du cœur artificiel.
Website address
http://www.carmatsas.com
Issuer website
http://www.carmatsas.com
Operation
IPO date
Qua 07/07/2010
IPO type
Initial Public offering
Catégorie
IPO